Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution
Journal Title: Journal of Radiology and Oncology - Year 2017, Vol 1, Issue 3
Abstract
Ra-223 dichloride is a first-in-class alpha-emitting radiopharmaceutical recently introduced into clinical practice for treatment of men with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases. Due to the proven benefit on Overall Survival and the favorable toxicity profile, Ra-223 therapy is gaining widespread use in both US and Europe. In this article, we describe the routinary management of patients undergoing Ra-223 treatment in our Institution.
Authors and Affiliations
GA Follacchio, V Frantellizzi, F Monteleone, G De Vincentis, M Liberatore
Keywords
Related Articles
- EP ID EP541157
- DOI 10.29328/journal.jro.1001010
- Views 67
- Downloads 0
Empirical formulae for calculating γ-ray detectors effective solid angle ratio
Determination of the detector efficiency using volumetric cylindrical sources is very important in various scientific and industrial fields, especially in the field of quantitative analysis. To calculate the absolute act...
Clinically and Radiological isolated syndrome (MS risk)
Background: The use of brain magnetic resonance imaging (MRI) for evaluation of neurological disorders has increased in the past two decades. This has led to an increased detection of incidental findings on brain MRI. Th...
Photon Absorption characteristics of some selected Enzyme Inhibitors used in Cancer Research in the Energy range 1 keV-100 GeV
The absorption parameters such as total mass attenuation coefficients, molecular, atomic, and electronic cross sections, effective atomic numbers and electron densities were calculated for some selected enzyme inhibitors...
Incidental findings in traditional nuclear medicine practice
The presence of an incidental finding, defined as an abnormality which is unrelated to the initial scanning indication, is widely increases due to the access to new devices and imaging modalities. This growing number of...
Near Complete Response to 177Lu-PSMA-DKFZ-617 Therapy in a Patient with Metastatic Castration Resistant Prostate Cancer
Prostate specific membrane antigen, a type II transmembrane protein is an excellent target for the radionuclide therapy in advanced prostate cancer patients due to its high expression in the prostate cancer cells. We pre...